Whether Viatris Korea, which owns the original atorvastatin ‘Lipitor,’ will be able to perform as well in the ‘ezetimibe’ combination therapy market, is drawing attention.

Recently, the use of combination therapy in dyslipidemia patients has become more than a strategic treatment option - it has become a main trend in the market.

In line with the trend, Viatris Korea, which has been leading the dyslipidemia treatment market with its ‘Lipitor(atorvastatin), and Jeil Pharmaceutical have jointly launched ‘Lipitor Plus,' a combination drug that contains atorvastatin and ezetimibe.

With many combination therapies containing the same substances already in the market, whe